Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations

Heart Rhythm

Volumn 9, Issue 3, 2012, Pages 422-429

  Sicouri, Serge ^a   Pourrier, Marc ^b   Gibson, John K ^c   Lynch, Joseph J ^d   Antzelevitch, Charles ^a  

^a MASONIC MEDICAL RESEARCH LABORATORY   (United States)

^b Cardiome Pharma Corp   (Canada)

^c AAKVSL Pharma Consulting LLC   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Antiarrhythmic drug; Atrial fibrillation; Electrophysiology; Pharmacology; Sodium channel blocker; Trigerred activity

Indexed keywords

RANOLAZINE; SOTALOL; VERNAKALANT;

ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; ARTICLE; CARDIOVASCULAR PARAMETERS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; HEART ELECTROPHYSIOLOGY; HEART MUSCLE REFRACTORY PERIOD; HEART REPOLARIZATION; MAXIMUM RATE OF RISE IN THE ACTION POTENTIAL UPSTROKE; NONHUMAN; PRIORITY JOURNAL; PULMONARY VEIN; PULMONARY VEIN SLEEVE;

ACETANILIDES; ACTION POTENTIALS; ADRENERGIC BETA-AGONISTS; ANIMALS; ANISOLES; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; BIOLOGICAL AVAILABILITY; CARDIAC ELECTROPHYSIOLOGY; CELL MEMBRANE; DOGS; HEART RATE; HUMANS; ISOPROTERENOL; MEMBRANE POTENTIALS; PIPERAZINES; PULMONARY VEINS; PYRROLIDINES; SODIUM CHANNELS; SOTALOL;

EID: 84857584648     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2011.10.021     Document Type: Article

References (52)

1. J. Bechard, J.K. Gibson, C.R. Killingsworth Vernakalant selectively prolongs atrial refractoriness with no effect on ventricular refractoriness or defibrillation threshold in pigs J Cardiovasc Pharmacol 57 2011 302 307
2. J.R. Ehrlich, S. Nattel Atrial-selective pharmacological therapy for atrial fibrillation: hype or hope? Curr Opin Cardiol 24 2009 50 55
3. D. Fedida Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent Expert Opin Investig Drugs 16 2007 519 532 (Pubitemid 46554469)
4. D. Fedida, P.M. Orth, J.Y. Chen The mechanism of atrial antiarrhythmic action of RSD1235 J Cardiovasc Electrophysiol 16 2005 1227 1238
5. S. Sicouri, A. Glass, L. Belardinelli, C. Antzelevitch Antiarrhythmic effects of ranolazine in canine pulmonary vein sleeve preparations Heart Rhythm 5 2008 1019 1026
6. J. Brachmann, T. Beyer, C. Schmitt Electrophysiologic and antiarrhythmic effects of d-sotalol J Cardiovasc Pharmacol 20 II 1992 91 95
7. G. Opolski, A. Torbicki, D.A. Kosior Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study Chest 126 2004 476 486 (Pubitemid 39093433)
8. S.C. Reimold, C.O. Cantillon, P.L. Friedman, E.M. Antman Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation Am J Cardiol 71 1993 558 563 (Pubitemid 23065009)
9. M. Haissaguerre, P. Jais, D.C. Shah Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins N Engl J Med 339 1998 659 666 (Pubitemid 28402090)
10. S. Sicouri, L. Belardinelli, L. Carlsson, C. Antzelevitch Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations J Cardiovasc Electrophysiol 20 2009 803 810
11. A. Burashnikov, C. Antzelevitch Late-phase 3 EAD: a unique mechanism contributing to initiation of atrial fibrillation Pacing Clin Electrophysiol 29 2006 290 295 (Pubitemid 43881405)
12. E. Patterson, S.S. Po, B.J. Scherlag, R. Lazzara Triggered firing in pulmonary veins initiated by in vitro autonomic nerve stimulation Heart Rhythm 2 2005 624 631 (Pubitemid 40724130)
13. 2+ transient: an arrhythmia trigger within pulmonary veins J Am Coll Cardiol 47 2006 1196 1206
14. W. Wongcharoen, Y.C. Chen, Y.J. Chen Aging increases pulmonary veins arrhythmogenesis and susceptibility to calcium regulation agents Heart Rhythm 4 2007 1338 1349 (Pubitemid 47495729)
15. L.W. Lo, Y.C. Chen, Y.J. Chen Calmodulin kinase II inhibition prevents arrhythmic activity induced by alpha and beta adrenergic agonists in rabbit pulmonary veins Eur J Pharmacol 571 2007 197 208
16. S. Sicouri, L. Carlsson, C. Antzelevitch Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves J Pharmacol Exp Ther 334 2010 255 259
17. S. Sicouri, B. Gianetti, A.C. Zygmunt, J.M. Cordeiro, C. Antzelevitch Antiarrhythmic effects of simvastatin in canine pulmonary vein sleeve preparations J Am Coll Cardiol 57 2011 986 993
18. M. Haissaguerre, P. Jais, D.C. Shah Electrophysiological end point for catheter ablation of atrial fibrillation initiated from multiple pulmonary venous foci Circulation 101 2000 1409 1417 (Pubitemid 30169863)
19. S. Nattel, M.A. Allessie, M. Haissaguerre Spotlight on atrial fibrillationthe "complete arrhythmia." Cardiovasc Res 54 2002 197 203 (Pubitemid 34327900)
20. S. Nattel Combined parasympatheticsympathetic nerve discharge and pulmonary vein afterdepolarizations: a new unifying concept with basic and clinical relevance Heart Rhythm 2 2005 632 633 (Pubitemid 40724131)
21. Y.J. Chen, S.A. Chen, M.S. Chang, C.I. Lin Arrhythmogenic activity of cardiac muscle in pulmonary veins of the dog: implication for the genesis of atrial fibrillation Cardiovasc Res 48 2000 265 273
22. Y.J. Chen, S.A. Chen Electrophysiology of pulmonary veins J Cardiovasc Electrophysiol 17 2006 220 224
23. S. Sicouri, A. Glass, L. Carlsson, C. Antzelevitch Electrophysiologic and antiarrhythmic effects of AZD1305 in canine pulmonary vein sleeves Heart Rhythm 5S 2008 S163
24. A. Burashnikov, C. Antzelevitch Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity Circulation 107 2003 2355 2360 (Pubitemid 36578508)
25. D. Roy, C.M. Pratt, C. Torp-Pedersen Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial Circulation 117 2008 1518 1525 (Pubitemid 351440640)
26. I.G. Stiell, J.S. Roos, K.M. Kavanagh, G. Dickinson A multicenter, open-label study of vernakalant for the conversion of atrial fibrillation to sinus rhythm Am Heart J 159 2010 1095 1101
27. B.D. Lindsay Vernakalant: additional evidence for safety and efficacy for new onset atrial fibrillation J Am Coll Cardiol 52 2011 322 323
28. v1.5 channels Mol Pharmacol 72 2007 1522 1534 (Pubitemid 350146089)
29. P. Dorian, A. Pinter, I. Mangat The effect of vernakalant (RSD1235): an investigational antiarrhythmic agent, on atrial electrophysiology in humans J Cardiovasc Pharmacol 50 2007 35 40 (Pubitemid 47220444)
30. I. Savelieva, J. Camm Anti-arrhythmic drug therapy for atrial fibrillation: current anti-arrhythmic drugs, investigational agents, and innovative approaches Europace 10 2008 647 665 (Pubitemid 351775283)
31. A. Burashnikov, J.M. Di Diego, A.C. Zygmunt, L. Belardinelli, C. Antzelevitch Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine Circulation 116 2007 1449 1457 (Pubitemid 47480635)
32. A.I. Undrovinas, L. Belardinelli, N.A. Undrovinas, H.N. Sabbah Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current J Cardiovasc Electrophysiol 17 2006 S161 S177
33. C. Antzelevitch, L. Belardinelli, A.C. Zygmunt Electrophysiologic effects of ranolazine: a novel anti-anginal agent with antiarrhythmic properties Circulation 110 2004 904 910 (Pubitemid 39136212)
34. C. Antzelevitch, L. Belardinelli, L. Wu Electrophysiologic properties and antiarrhythmic actions of a novel anti-anginal agent J Cardiovasc Pharmacol Ther 9 2004 S65 S83
35. i and the emerging involvement of the late sodium current in the pathophysiology of cardiovascular disease Eur Heart J Suppl 8 2006 A6 A9
36. M.R. Rosen, P. Danilo Jr Effects of tetrodotoxin, lidocaine, verapamil and AHR-266 on ouabain induced delayed afterdepolarizations in canine Purkinje fibers Circ Res 46 1980 117 124 (Pubitemid 10199445)
37. B.N. Singh, K. Nademanee Sotalol: a beta blocker with unique antiarrhythmic properties Am Heart J 114 1987 121 139 (Pubitemid 17098552)
38. N. Freemantle, C. Lafuente-Lafuente, S. Mitchell, L. Eckert, M. Reynolds Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide and propafenone for the management of atrial fibrillation Europace 13 2011 329 345
39. T.J. Campbell Cellular electrophysiological effects of d- and dl-sotalol in guinea-pig sinoatrial node, atrium and ventricle and human atrium: differential tissue sensitivity Br J Pharmacol 90 1987 593 599 (Pubitemid 17022607)
40. E. Patterson, B.J. Scherlag, R. Lazzara Early afterdepolarizations produced by d,l-sotalol and clofilium J Cardiovasc Electrophysiol 8 1997 667 678 (Pubitemid 27265863)
41. B.I. Sasyniuk, S. Brunet Torsade de pointes induced by quinidine, d-sotalol, and E-4031 in the isolated rabbit heart: importance of interval dependent dispersion of repolarization Pacing Clin Electrophysiol 18 1995 II-904
42. S. Sicouri, S. Moro, M.V. Elizari d-Sotalol induces marked action potential prolongation and early afterdepolarizations in M but not epicardial or endocardial cells of the canine ventricle J Cardiovasc Pharmacol Ther 2 1997 27 38 (Pubitemid 27157110)
43. S.H. Hohnloser Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management Am J Cardiol 80 1997 82G 89G (Pubitemid 27469748)
44. A. Marinelli, A. Capucci Antiarrhythmic drugs for atrial fibrillation Expert Opin Pharmacother 12 2011 1201 1215
45. Camm AJ. Antiarrhythmic drugs for the maintenance of sinus rhythm: risks and benefits. Int J Cardiol. In Press. doi:10.1016/j.ijcard.2011.06.012.
46. C. Torp-Pedersen, D.H. Raev, G. Dickinson et al. A randomized placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence post-cardioversion Circ Arrhythm Electrophysiol 4 2011 637 643
47. C. Antzelevitch, A. Burashnikov Atrial-selective sodium channel block as a novel strategy for the management of atrial fibrillation J Electrocardiol 42 2009 543 548
48. D.K. Murdock, M. Kersten, J. Kaliebe, G. Larrian The use of oral ranolazine to convert new or paroxysmal atrial fibrillation: a review of experience with implications for possible "pill in the pocket" approach to atrial fibrillation Indian Pacing Electrophysiol J 9 2009 260 267
49. D.K. Murdock, J.A. Reiffel, J.W. Kaliebe, G. Larrian The conversion of paroxysmal of initial onset of atrial fibrillation with oral ranolazine: implications for "pill in the pocket" approach in structural heart disease J Am Coll Cardiol 55 Suppl 2010 A6.E58 Abstract
50. C. Antzelevitch, A. Burashnikov, S. Sicouri, L. Belardinelli Electrophysiological basis for the antiarrhythmic actions of ranolazine Heart Rhythm 8 2011 1281 1290
51. D.K. Murdock, R.S. Passman, H. Subacius, R.H. Miles Ranolazine verses amiodarone for atrial fibrillation prophylaxis following coronary bypass surgery J Am Coll Cardiol 57 2011 E155
52. S.H. Hohnloser, B.N. Singh Proarrhythmia with class III antiarrhythmic drugs: definition, electrophysiologic mechanisms, incidence, predisposing factors and clinical implications J Cardiovasc Electrophysiol 6 1995 920 936